Published in Am J Med on March 01, 2002
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev (2010) 3.11
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem (2007) 2.73
Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res (2010) 2.52
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res (2012) 2.05
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ (2009) 2.00
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int (2013) 1.79
Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int (2007) 1.79
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
What old means to bone. Trends Endocrinol Metab (2010) 1.64
Ultrasonic bone assessment: "the time has come". Bone (2006) 1.61
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int (2005) 1.61
Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment. Bone (2012) 1.60
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int (2006) 1.55
A biomechanical perspective on bone quality. Bone (2006) 1.53
Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry. Osteoporos Int (2007) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy. J Bone Miner Res (2013) 1.46
Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. J Biomed Mater Res A (2010) 1.45
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int (2009) 1.44
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone (2010) 1.41
The epidemiology of distal radius fractures. Hand Clin (2012) 1.40
Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders. Osteoporos Int (2016) 1.38
Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int (2009) 1.37
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Automated registration of hip and spine for longitudinal QCT studies: integration with 3D densitometric and structural analysis. Bone (2005) 1.29
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab (2012) 1.27
The assessment of fracture risk. J Bone Joint Surg Am (2010) 1.27
Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res (2008) 1.16
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int (2008) 1.14
How can bone turnover modify bone strength independent of bone mass? Bone (2008) 1.13
Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int (2006) 1.12
A biomechanical analysis of the effects of resorption cavities on cancellous bone strength. J Bone Miner Res (2006) 1.11
Role of trabecular microarchitecture in whole-vertebral body biomechanical behavior. J Bone Miner Res (2009) 1.08
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int (2004) 1.07
Qualitative and quantitative ultrashort-TE MRI of cortical bone. NMR Biomed (2012) 1.06
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Compressive axial mechanical properties of rat bone as functions of bone volume fraction, apparent density and micro-ct based mineral density. J Biomech (2009) 1.04
Microstructure and nanomechanical properties in osteons relate to tissue and animal age. J Biomech (2010) 1.03
Monitoring drug therapy. Br J Clin Pharmacol (2012) 1.02
Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev (2006) 1.01
Treatment of postmenopausal osteoporosis. BMJ (2003) 1.00
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int (2007) 1.00
Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int (2008) 0.99
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. J Med Device (2013) 0.98
Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res (2009) 0.98
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone (2014) 0.96
Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition. Aging Cell (2010) 0.95
Understanding compliance issues for daily self-injectable treatment in ambulatory care settings. Patient Prefer Adherence (2008) 0.94
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther (2012) 0.94
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int (2009) 0.94
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int (2011) 0.93
Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy. J Bone Miner Metab (2006) 0.93
Evaluation of compressive strength index of the femoral neck in Caucasians and chinese. Calcif Tissue Int (2010) 0.92
Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int (2006) 0.92
Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy. Bone (2010) 0.92
Is bone quality associated with collagen age? Osteoporos Int (2009) 0.91
Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporos Int (2006) 0.91
Bone microarchitecture and strength. Osteoporos Int (2003) 0.91
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab (2006) 0.90
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int (2007) 0.90
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int (2010) 0.89
Patient willingness to take teriparatide. Patient Educ Couns (2006) 0.89
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int (2014) 0.88
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method. J Bone Miner Metab (2011) 0.88
Exercise and bone mineral density in premenopausal women: a meta-analysis of randomized controlled trials. Int J Endocrinol (2013) 0.88
Skeletal fragility definition. Clin Cases Miner Bone Metab (2011) 0.88
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab (2010) 0.87
Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int (2010) 0.87
Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med (2010) 0.87
Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed (2005) 0.87
Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone. J Bone Miner Res (2010) 0.87
Age-specific profiles of tissue-level composition and mechanical properties in murine cortical bone. Bone (2012) 0.87
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int (2012) 0.87
Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures. Osteoporos Int (2006) 0.87
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J (2008) 0.86
Bisphosphonate use in acute and chronic spinal cord injury: a systematic review. J Spinal Cord Med (2009) 0.86
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2016) 0.86
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int (2008) 0.85
Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS). Osteoporos Int (2013) 0.85
A computational assessment of the independent contribution of changes in canine trabecular bone volume fraction and microarchitecture to increased bone strength with suppression of bone turnover. J Biomech (2007) 0.85
Parametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis. Bone (2012) 0.84
Reduced tissue-level stiffness and mineralization in osteoporotic cancellous bone. Calcif Tissue Int (2014) 0.83
Advances in therapy for osteoporosis. Clin Med Res (2003) 0.83
Use of randomised trials to decide when to monitor response to new treatment. BMJ (2008) 0.83
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.83
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporos Int (2014) 0.82
The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int (2008) 0.82
Association between dietary intake of flavonoid and bone mineral density in middle aged and elderly Chinese women and men. Osteoporos Int (2014) 0.82
Choice of study phenotype in osteoporosis genetic research. J Bone Miner Metab (2009) 0.82
The influence of orthopedic corsets on the incidence of pathological fractures in patients with spinal bone metastases after radiotherapy. BMC Cancer (2015) 0.82
Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis. J Bone Miner Metab (2010) 0.81
Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. Osteoporos Int (2009) 0.81
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med (2006) 6.22
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am (2002) 5.95
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res (2010) 3.33
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc (2005) 3.02
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Musculoskeletal ultrasound in rheumatology: a radiologic perspective. Arthritis Rheum (2005) 2.71
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation (2007) 2.50
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48
The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.42
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Protein intake and incident frailty in the Women's Health Initiative observational study. J Am Geriatr Soc (2010) 2.28
Older adults' views of "successful aging"--how do they compare with researchers' definitions? J Am Geriatr Soc (2004) 2.24
The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum (2004) 2.22
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ (2009) 2.00
Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ (2009) 1.99
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Effects of provider practice on functional independence in older adults. J Am Geriatr Soc (2004) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res (2004) 1.93
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Factors associated with kyphosis progression in older women: 15 years' experience in the study of osteoporotic fractures. J Bone Miner Res (2013) 1.84
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int (2005) 1.82
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res (2005) 1.76
Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol (2002) 1.75
Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol A Biol Sci Med Sci (2013) 1.74
Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res (2009) 1.73
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
Associations between body composition, anthropometry, and mortality in women aged 65 years and older. Am J Public Health (2007) 1.72
SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med (2002) 1.71
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr (2010) 1.67
Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause (2014) 1.67
Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med (2011) 1.64
Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum (2005) 1.64
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril (2012) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study. Am J Clin Nutr (2014) 1.60
Association between sleep and physical function in older men: the osteoporotic fractures in men sleep study. J Am Geriatr Soc (2008) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res (2012) 1.58
Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res (2009) 1.58
Prehemodialysis care by dietitians and first-year mortality after initiation of hemodialysis. Am J Kidney Dis (2011) 1.57
Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause (2011) 1.56
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc (2015) 1.54
Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diabetes Care (2003) 1.52
BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res (2011) 1.51
Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res (2008) 1.51
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res (2012) 1.50
Baseline age and time to major fracture in younger postmenopausal women. Menopause (2015) 1.49
Reliability and validity of the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale in older men. J Gerontol A Biol Sci Med Sci (2011) 1.46
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res (2006) 1.45
Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause (2007) 1.44